STA
AGIO icon

Summit Trail Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Summit Trail Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-282
Closed -$20K – 443
2017
Q4 		$20K Buy
+282
New +$17.7K ﹤0.01% 1036

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Summit Trail Advisors's AGIO Position: Q1 2018 in Review

Summit Trail Advisors sold out of Agios Pharmaceuticals (AGIO) in Q1 2018, closing a stake of 282 shares — an estimated $20K sold.

Summit Trail Advisors first reported a position in AGIO in Q4 2017 and held it in 1 quarter. The position peaked at $20K in Q4 2017. 198 funds tracked by Wall St. Rank hold AGIO as of Q1 2018.

  • Summit Trail Advisors reported no remaining Agios Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 282 Agios Pharmaceuticals shares in Q1 2018, an estimated $20K.
  • Summit Trail Advisors first reported a position in Agios Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Agios Pharmaceuticals position peaked at $20K in Q4 2017.
  • 198 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.